FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282913306> ?p ?o ?g. }

• W4282913306 abstract "Malaria is a major cause of morbidity and mortality globally, especially in sub-Saharan Africa. Widespread resistance to pyrethroids threatens the gains achieved by vector control. To counter resistance to pyrethroids, third-generation indoor residual spraying (3GIRS) products have been developed. This study details the results of a multi-country cost and cost-effectiveness analysis of indoor residual spraying (IRS) programmes using Actellic®300CS, a 3GIRS product with pirimiphos-methyl, in sub-Saharan Africa in 2017 added to standard malaria control interventions including insecticide-treated bed nets versus standard malaria control interventions alone.An economic evaluation of 3GIRS using Actellic®300CS in a broad range of sub-Saharan African settings was conducted using a variety of primary data collection and evidence synthesis methods. Four IRS programmes in Ghana, Mali, Uganda, and Zambia were included in the effectiveness analysis. Cost data come from six IRS programmes: one in each of the four countries where effect was measured plus Mozambique and a separate programme conducted by AngloGold Ashanti Malaria Control in Ghana. Financial and economic costs were quantified and valued. The main indicator for the cost was cost per person targeted. Country-specific case incidence rate ratios (IRRs), estimated by comparing IRS study districts to adjacent non-IRS study districts or facilities, were used to calculate cases averted in each study area. A deterministic analysis and sensitivity analysis were conducted in each of the four countries for which effectiveness evaluations were available. Probabilistic sensitivity analysis was used to generate plausibility bounds around the incremental cost-effectiveness ratio estimates for adding IRS to other standard interventions in each study setting as well as jointly utilizing data on effect and cost across all settings.Overall, IRRs from each country indicated that adding IRS with Actellic®300CS to the local standard intervention package was protective compared to the standard intervention package alone (IRR 0.67, [95% CI 0.50-0.91]). Results indicate that Actellic®300CS is expected to be a cost-effective (> 60% probability of being cost-effective in all settings) or highly cost-effective intervention across a range of transmission settings in sub-Saharan Africa.Variations in the incremental costs and cost-effectiveness likely result from several sources including: variation in the sprayed wall surfaces and house size relative to household population, the underlying malaria burden in the communities sprayed, the effectiveness of 3GIRS in different settings, and insecticide price. Programmes should be aware that current recommendations to rotate can mean variation and uncertainty in budgets; programmes should consider this in their insecticide-resistance management strategies.The optimal combination of 3GIRS delivery with other malaria control interventions will be highly context specific. 3GIRS using Actellic®300CS is expected to deliver acceptable value for money in a broad range of sub-Saharan African malaria transmission settings." @default.
• W4282913306 created "2022-06-16" @default.
• W4282913306 creator A5003938190 @default.
• W4282913306 creator A5004023837 @default.
• W4282913306 creator A5008777069 @default.
• W4282913306 creator A5012154455 @default.
• W4282913306 creator A5013757298 @default.
• W4282913306 creator A5013835803 @default.
• W4282913306 creator A5014393718 @default.
• W4282913306 creator A5016730184 @default.
• W4282913306 creator A5021714367 @default.
• W4282913306 creator A5023252580 @default.
• W4282913306 creator A5026454536 @default.
• W4282913306 creator A5030072310 @default.
• W4282913306 creator A5033590161 @default.
• W4282913306 creator A5035814832 @default.
• W4282913306 creator A5036815501 @default.
• W4282913306 creator A5039330243 @default.
• W4282913306 creator A5040641269 @default.
• W4282913306 creator A5044088542 @default.
• W4282913306 creator A5048608878 @default.
• W4282913306 creator A5048938974 @default.
• W4282913306 creator A5054207326 @default.
• W4282913306 creator A5058019143 @default.
• W4282913306 creator A5062520744 @default.
• W4282913306 creator A5063755421 @default.
• W4282913306 creator A5064946614 @default.
• W4282913306 creator A5067343193 @default.
• W4282913306 creator A5069868823 @default.
• W4282913306 creator A5072984452 @default.
• W4282913306 creator A5073846805 @default.
• W4282913306 creator A5074212751 @default.
• W4282913306 creator A5074723590 @default.
• W4282913306 creator A5074927073 @default.
• W4282913306 creator A5076139117 @default.
• W4282913306 creator A5078198798 @default.
• W4282913306 creator A5078741126 @default.
• W4282913306 creator A5078792522 @default.
• W4282913306 creator A5080061259 @default.
• W4282913306 creator A5081508780 @default.
• W4282913306 creator A5081713866 @default.
• W4282913306 creator A5085914344 @default.
• W4282913306 creator A5087130249 @default.
• W4282913306 date "2022-06-11" @default.
• W4282913306 modified "2023-10-14" @default.
• W4282913306 title "Incremental cost and cost-effectiveness of the addition of indoor residual spraying with pirimiphos-methyl in sub-Saharan Africa versus standard malaria control: results of data collection and analysis in the Next Generation Indoor Residual Sprays (NgenIRS) project, an economic-evaluation" @default.
• W4282913306 cites W1513618424 @default.
• W4282913306 cites W1729017034 @default.
• W4282913306 cites W1975146217 @default.
• W4282913306 cites W2107328434 @default.
• W4282913306 cites W2112941164 @default.
• W4282913306 cites W2146683831 @default.
• W4282913306 cites W2256068279 @default.
• W4282913306 cites W2342193003 @default.
• W4282913306 cites W2557867537 @default.
• W4282913306 cites W2572433128 @default.
• W4282913306 cites W2615833501 @default.
• W4282913306 cites W2783522612 @default.
• W4282913306 cites W2980399877 @default.
• W4282913306 cites W3041732131 @default.
• W4282913306 cites W3110194737 @default.
• W4282913306 cites W3122264220 @default.
• W4282913306 cites W3128497307 @default.
• W4282913306 cites W3132521651 @default.
• W4282913306 cites W3150532334 @default.
• W4282913306 cites W3160550928 @default.
• W4282913306 cites W4206006624 @default.
• W4282913306 cites W4206071468 @default.
• W4282913306 doi "https://doi.org/10.1186/s12936-022-04160-3" @default.
• W4282913306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35690756" @default.
• W4282913306 hasPublicationYear "2022" @default.
• W4282913306 type Work @default.
• W4282913306 citedByCount "1" @default.
• W4282913306 countsByYear W42829133062022 @default.
• W4282913306 crossrefType "journal-article" @default.
• W4282913306 hasAuthorship W4282913306A5003938190 @default.
• W4282913306 hasAuthorship W4282913306A5004023837 @default.
• W4282913306 hasAuthorship W4282913306A5008777069 @default.
• W4282913306 hasAuthorship W4282913306A5012154455 @default.
• W4282913306 hasAuthorship W4282913306A5013757298 @default.
• W4282913306 hasAuthorship W4282913306A5013835803 @default.
• W4282913306 hasAuthorship W4282913306A5014393718 @default.
• W4282913306 hasAuthorship W4282913306A5016730184 @default.
• W4282913306 hasAuthorship W4282913306A5021714367 @default.
• W4282913306 hasAuthorship W4282913306A5023252580 @default.
• W4282913306 hasAuthorship W4282913306A5026454536 @default.
• W4282913306 hasAuthorship W4282913306A5030072310 @default.
• W4282913306 hasAuthorship W4282913306A5033590161 @default.
• W4282913306 hasAuthorship W4282913306A5035814832 @default.
• W4282913306 hasAuthorship W4282913306A5036815501 @default.
• W4282913306 hasAuthorship W4282913306A5039330243 @default.
• W4282913306 hasAuthorship W4282913306A5040641269 @default.
• W4282913306 hasAuthorship W4282913306A5044088542 @default.
• W4282913306 hasAuthorship W4282913306A5048608878 @default.
• W4282913306 hasAuthorship W4282913306A5048938974 @default.
• W4282913306 hasAuthorship W4282913306A5054207326 @default.
• W4282913306 hasAuthorship W4282913306A5058019143 @default.
• W4282913306 hasAuthorship W4282913306A5062520744 @default.
• W4282913306 hasAuthorship W4282913306A5063755421 @default.
• W4282913306 hasAuthorship W4282913306A5064946614 @default.

• next